

D:A:D Newsletter



December 2014

The staff at the D:A:D Coordinating Centre (CC) would like to wish you all a Happy Holiday and a Happy New Year, and to thank everyone for their contribution to the study over the past year. In this newsletter we would like to take the opportunity to provide you with the latest news and study updates. Please distribute this newsletter to all involved with the study at your centre.

GENERAL INFORMATION

Numbers from the 15th Data Merger show that a total of 49,711 HIV-positive persons from more than 210 centres have now accrued in the D:A:D study, comprising a total of 421,125 person years of follow-up. Further, over the 15 years that the study has now been running, we have confirmed reports of 1008 myocardial infarctions, 1140 invasive coronary procedures, 463 strokes, 1656 diabetes and 1469 non-AIDS defining cancers. Approximately 90 people are known to have end stage renal disease while around 320 people have end stage liver disease. A total of around 4743 people have died.

EVENT CASE REPORT FORMS (CRFs)

The detailed reporting of information pertaining to each event through completion of the standardized CRF is a critical component of the continued success of the D:A:D Study. Thanks to all our colleagues who continue to contribute to this great effort. The medical staff at the CC review all forms received and will continue to ask centres for further clarifications and/or additional information for events when this is necessary. This will ensure that we are able to classify the events appropriately according to our standard algorithms. We thank all the centres for their efforts in trying to solve pending queries.

For the continued success of the study, it also remains critical that all the incident cases of the study endpoints are reported in a timely and detailed manner. We encourage the sites to continue to closely follow patients involved in the D:A:D Study and to promptly report all relevant events to the CC.

In 2013 it was decided to include ascites as an additional criteria for end stage liver disease. This implies clinically identifiable and detectable ascites confirmed by imaging with no other known non- liver related cause. At the SC F2F meeting in Nice on November 18th, 2014, it was agreed to proceed with implementation of a new CRF, including ascites, from January

D:A:D STEERING COMMITTEE (SC) MEETING

The next D:A:D SC F2F meeting will be held Tuesday February 24th, 2015 at CROI in Seattle.

RECENT PUBLICATIONS:

Also available at:

<http://www.cphiv.dk/Ongoing-Studies/DAD/Publications>

Publications 2014:

1. Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons in the D:A:D study.

L Ryom, A Mocroft, O Kirk, M Ross, P Reiss, CA Fux, P Morlat, O Moranne, C Smith, W El-Sadr, M Law, JD Lundgren et al. for the D:A:D study group. AIDS. 2014 Jan 14;28(2):187-99.

2. Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study.

DA Kamara/L Ryom, M Ross, O Kirk, P Reiss, P Morlat, O Moranne, CA Fux, A Mocroft, CA Sabin, JD Lundgren, CJ Smith. BMC Nephrol. 2014 Mar 25;15(1).

3. Increased risk of cardiovascular disease (CVD)

1st, 2015. The updated CRF and instructions on how to use the criteria will be circulated to all participating cohorts no later than December 20th and will also be made available on the CHIP website. We anticipate that a revised MOOP will be ready later in 2015.

UPCOMING DEADLINES, EVENT QUERY AND MERGER 16

During Winter 2015 all cohorts will receive a list of pending events including

- Events not yet reported
- Events with outstanding/incomplete source documentation
- Events with a date discrepancy

Please send all outstanding events to the D:A:D CC before April 3rd, 2015. Detailed listings of events will be e-mailed in mid-February, 2015.

The data submission deadline for Merger 16 is 1st of June 2015.

RECENT PRESENTATIONS

Also available at: <http://www.chip.dk/Ongoing-Studies/DAD/Presentations>

Presentations 2014:

21th Conference on Retroviruses and Opportunistic Infections, Boston, February 2014

Poster presentations

1. Association between dideoxynucleoside analogues (d-drugs) and end-stage liver disease (ESLD)

L Ryom, CA Sabin, P Reiss, W El-Sadr, AD Monforte, S De Wit, MG Law, O Kirk, AN Phillips and JD Lundgren for the D:A:D study group.

2. Predictors of progression, stabilisation or improvement of eGFR after chronic renal impairment

L Ryom, A Mocroft, O Kirk, P Reiss, M Ross, O Moranne, P Morlat, CJ Smith, CA Fux and JD Lundgren for the D:A:D study group.

3. Is there continued evidence for an association between abacavir and myocardial infarction risk?

CA Sabin, P Reiss, L Ryom, S de Wit, O Kirk, R Weber, C Pradier, F Dabis, AN Phillips, JD Lundgren for the D:A:D study group.

World AIDS Conference, Melbourne, July 2014

with age in HIV positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations.

K Petoumenos , P Reiss , L Ryom, M Rickenbach, CA Sabin, W El-Sadr, AD Monforte A Phillips , S De Wit, O Kirk , F , Dabis C , Pradier, JD Lundgren , MG Law, D:A:D study group. HIV Med. 2014 Nov;15(10):595-603.

4. Trends in underlying causes of death in people with HIV from 1999-2011 (D:A:D): a multicohort collaboration.

CJ Smith, L Ryom, R Weber, P Morlat, C Pradier, P Reiss, JD Kowalska, S de Wit, MG Law, W el Sadr, O Kirk, N Friis-Møller, AD Monforte, AN Phillips, CA Sabin, JD Lundgren, D:A:D Study Group. Lancet. 2014 Jul 19;384(9939):241-8.

5. Cancer risk and use of protease inhibitor or non-nucleoside reverse transcriptase inhibitor based combination antiretroviral therapy: the D:A:D study.

M Bruyand, L Ryom, L Shepherd, G Fatkenheuer, A Grulich, P Reiss, S de Wit, AD Monforte, H Furrer, C Pradier, JD Lundgren, CA Sabin for the D:A:D study group. In press in JAIDS.

6. Short-term change in body mass index after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes in HIV-positive individuals: the D:A:D study.

AC Achhra , A Mocroft, P Reiss , CA Sabin L Ryom , S de Wit , C J Smith , A D Monforte , A Phillips , R Weber , JD Lundgren, MG Law , The D:A:D Study Group. Resubmitted to JID.

7. Prediction of global CVD risk in HIV-positive persons.

N Friis-Møller, L Ryom, CJ Smith, R Weber, P Reiss, F Dabis, S De Wit, AD

Oral Presentation

Impact of short-term change in body mass index after antiretroviral therapy initiation on subsequent risk of cardiovascular disease and diabetes in HIV-positive individuals: the D:A:D study

AC Achhra, A Mocroft, P Reiss, CA Sabin, L Ryom, S de Wit, CJ Smith, AD Monforte, A Phillips, R Weber, JD Lundgren, MG Law, The D:A:D Study Group.

12th International Congress on Drug Therapy in HIV Infection, Glasgow, November 2014

Oral Presentations

1. Lack of Association Between Use of Efavirenz and Death from Suicide: D:A:D Study

CJ Smith, L Ryom, AD Monforte, P Reiss, A Mocroft, W el Sadr, R Weber, MG Law, CA Sabin, JD Lundgren for the D:A:D Study Group.

2. A clinically useful risk-score for chronic kidney disease (CKD) in HIV infection

A Mocroft, JD Lundgren, M Ross, MG Law, P Reiss, O Kirk, CJ Smith, D Wentworth, J Neuhaus, CA Fux, O Moranne, P Morlat, MA Johnson, L Ryom on behalf of the Data on Adverse Events (D:A:D) study group, the Royal Free Hospital Clinic Cohort and the INSIGHT study group.

3. Gender Differences in the Use of Cardiovascular Disease-related Interventions Among HIV-positive persons: D:A:D Study

CI Hatleberg, L Ryom, W El-Sadr, A Mocroft, P Reiss, S de Wit, F Dabis, C Pradier, AD Monforte, M Rickenbach, MGLaw, JD Lundgren, CA Sabin for the D:A:D Study Group.

Presentations 2013:

20th Conference on Retroviruses and Opportunistic Infections, Atlanta, March 2013

Oral Presentation

Increased risk of cardiovascular disease (CVD) with age in men: a comparison of D:A:D with HIV negative CVD risk equation

K Petoumenos, W El-Sadr, AD Monforte, CA Sabin, P Reiss, L Ryom, S De Wit, M Rickenbach, JD Lundgren and MG Law for the D:A:D Study group.

Poster presentations

Monforte, O Kirk, E Fontas, CA Sabin, A Phillips, JD Lundgren, MG Law for the D:A:D Study Group. In review European Journal of Preventive Cardiology.

8. A clinically applicable risk-score for chronic kidney disease in HIV infection. A

Mocroft, JD Lundgren, M Ross, MG Law, P Reiss, O Kirk, CJ Smith, D Wentworth, J Neuhaus, CA Fux, O Moranne, P Morlat, MA Johnson, L Ryom on behalf of the Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study, the Royal Free Hospital Clinic Cohort and the INSIGHT study group. In review PLoS Med.

Publications 2013:

1. Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events.

AD Monforte, P Reiss, L Ryom, W El-Sadr, F Dabis, S De Wit, SW Worm, MG Law, R Weber, O Kirk, C Pradier, AN Phillips, JD Lundgren, CA Sabin. AIDS 2013 Jan 28;27(3):407-15.

2. Association between ALT level and the rate of cardio/cerebrovascular events in HIV-positive individuals: The D: A: D Study.

CA Sabin, L Ryom, H Kovari, O Kirk, S de Wit, MG Law, P Reiss, F Dabis, C Pradier, W El Sadr, AD Monforte, D Kamara, AN Phillips, JD Lundgren JD. J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):456-63.

3. Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study.

H Kovari, CA Sabin, B Ledergerber, L Ryom, SW Worm, CJ Smith, A Phillips, P Reiss, E Fontas, K Petoumenos, C

1. Cancer Risk and Use of PI or NNRTI-based Combination Antiretroviral Therapy (cART): The D:A:D Study.

M Bruyand, L Ryom, L Shepherd, P Reiss, S de Wit, AD Monforte, M Rickenbach, A Philips, C Pradier, MG Law, W El-Sadr, JD Lundgren, CA Sabin for the D:A:D study group.

2. Predictors of Advanced Chronic Kidney Disease and End-Stage Renal Disease in HIV-Positive Persons in D:A:D.

L Ryom, A Mocroft, O Kirk, M Ross, P Reiss, W El-Sadr, S de Wit, P Morlat, O Moranne, CA Fux, AD Monforte, MG Law and JD Lundgren for the D:A:D Study group.

3. Improvements in short-term mortality following myocardial infarction (MI): the D:A:D Study

CA Sabin, L Ryom, MG Law, W El-Sadr, O Kirk, M Bruyand, P Reiss, C Pradier, B Ledergerber, AD Monforte, S de Wit, JD Lundgren on behalf of the D:A:D Study Group.

International Workshop on HIV Observational Databases, IWHOD, Cavtat, April 2013

Oral Presentation

Investigating the causal impact of PI- and NNRTI-containing cART on the risk of mortality: methodological challenges

CJ Smith, D Ford, M Hernan, CA Sabin, P Reiss, S de Wit, AD Monforte, C Pradier, MG Law, R Weber, M Bruyand, W el-Sadr, A Phillips, L Ryom, JD Lundgren for the D:A:D Study Group.

14th European AIDS Conference, Brussels, October 2013

Oral Presentation

Prediction of global CVD risk in HIV-positive persons

N Friis Møller, L Ryom, CJ Smith, R Weber, P Reiss, F Dabis, S De Wit, AD Monforte, O Kirk, E Fontas, CA Sabin, A Phillips, JD Lundgren, MG Law for the D:A:D Study group.

Poster Presentation

Investigating the causal impact of PI- and NNRTI-containing cART on the risk of mortality: methodological challenges

CJ Smith, D Ford, M Hernan, CA Sabin, P Reiss, S de Wit, AD Monforte, C Pradier, MG Law, R Weber, M Bruyand, W el-Sadr, A Phillips, L Ryom, JD Lundgren for the D:A:D Study Group.

REISS, E FONTAS, R PETOUMENOS, S De Wit, P Morlat, JD Lundgren, R Weber. Clin Infect Dis. 2013 Mar;56(6):870-9.

4. Association Between Antiretroviral Exposure and Renal Impairment Among HIV-positive Persons with Normal Baseline Renal Function: the D:A:D study. L Ryom, A Mocroft, O Kirk, SW Worm, DA Kamara, P Reiss, M Ross, CA Fux, P Morlat, O Moranne, CJ Smith, JD Lundgren; on behalf of the D:A:D study group. J Infect Dis. 2013 May;207(9):1359-1369.

5. Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study.

SW Worm, M Bower, P Reiss, F Bonnet, MG Law, G Fätkenheuer, AD Monforte, DI Abrams, A Grulich, E Fontas, O Kirk, H Furrer, S De Wit, A Phillips, JD Lundgren, CA Sabin. BMC Infect Dis. 2013 Oct 9;13(1):471.

6. Associations between immune depression and cardiovascular events in HIV infection. CA Sabin, L Ryom, S De Wit, A Mocroft, AN Phillips, SW Worm, R Weber, AD Monforte, P Reiss, D Kamara, W El-Sadr, C Pradier, F Dabis, MG Law, JD Lundgren. AIDS. 2013 Nov 13;27(17):2735-2748.

UPCOMING CONFERENCES

CROI 2015, Seattle: 5 D:A:D abstracts have been accepted for presentation

Website: www.cphiv.dk

D:A:D Coordinating Secretariat:

CHIP (Centre for Health and Infectious Disease Research), Rigshospitalet, University of Copenhagen, Department of Infectious Diseases and Rheumatology, Section 2100, Finsencentret, Blegdamsvej 9, DK-2100 Copenhagen Ø, Denmark, Tel: +45 35 45 57 57, Fax: +45 35 45 57 58

Funding is recieved from: Please see under 'Financial acknowledgements' at:

<http://www.cphiv.dk/Ongoing-Studies/DAD/Study-Group>